TAP EN Article Feed

FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion–Positive Solid Tumors

The ASCO Post — Tue, 11 Aug 2026 12:49:45 +00:00

The oral RET inhibitor was approved for adult and pediatric patients aged 2 years and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, whose disease has progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

FDA Approves Radionuclide Therapy Plus ARPI for mAPMN/S Prostate Cancer

The ASCO Post — Tue, 11 Aug 2026 12:50:33 +00:00

Lutetium-177–labeled PSMA-617 (vipivotide tetraxetan, also known as LuPSMA-617; Pluvicto), a targeted radionuclide therapy, was approved for use in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen–positive metastatic androgen pathway modulation–naive or –sensitive (mAPMN/S) prostate cancer (commonly referred to as metastatic hormone-sensitive prostate cancer).

Teclistamab Improves Progression-Free and Overall Survival in Previously Treated Multiple Myeloma

The ASCO Post — Mon, 10 Aug 2026 02:52:39 +00:00

In the phase III MajesTEC-9 trial, teclistamab monotherapy was compared with investigator’s choice of pomalidomide/bortezomib/dexamethasone or carfilzomib/dexamethasone in patients with relapsed or refractory (R/R) multiple myeloma; investigators shared an interim analysis of survival and safety data in The New England Journal of Medicine.

Technology-Enabled Intervention for HCT Recipients, Primary Care Doctors May Improve Skin Cancer Screening

The ASCO Post — Mon, 10 Aug 2026 06:58:29 +00:00

Survivors of hematopoietic cell transplant (HCT) are at increased risk of skin cancer, and screening for early detection is encouraged. New research explores whether a cost-effective, scalable education program targeting survivors and their primary care doctors can significantly improve screening.

Phase III Trial Supports Intensified Total Neoadjuvant Therapy in High-Risk Rectal Cancer

The ASCO Post — Mon, 10 Aug 2026 06:15:57 +00:00

Researchers in China evaluated whether an intensified total neoadjuvant therapy approach integrating long-course radiotherapy with uninterrupted doublet chemotherapy (capecitabine plus oxaliplatin) improved disease-free survival compared with conventional neoadjuvant chemoradiotherapy in patients with high-risk locally advanced rectal cancer.

American College of Surgeons' Commission on Cancer Introduces Rural Cancer Program Accreditation

The ASCO Post — Mon, 10 Aug 2026 06:37:26 +00:00

The American College of Surgeons' Commission on Cancer has introduced a Rural Cancer Program Accreditation, providing a new accreditation pathway tailored to hospitals in rural counties, thereby expanding access to high-quality cancer care for individuals in rural communities.

Stanford Appoints New Leader to Expand Impact in Early Drug Development

The ASCO Post — Tue, 11 Aug 2026 01:06:35 +00:00

Pamela Munster, MD, joined the Stanford Cancer Institute as the inaugural Associate Director for Early Detection and Interception Research on August 1, 2026. She also assumed a faculty appointment as a Professor in the Stanford Medicine Division of Oncology.

NIH-Funded International Research Yields Patient-Derived Tumor Compendium

The ASCO Post — Tue, 11 Aug 2026 01:14:15 +00:00

The Human Cancer Models Initiative (HMCI), a decade-long effort, is now an internationally accessible resource of models and data. It is a collection that includes 665 next-generation laboratory models representing 25 types of cancer from 2,780 donors. HCMI has developed models for all the common subtypes of cancer, including most of the predominant genetic alterations within each subtype.

AI Biomarker May Guide Adjuvant Chemotherapy in Resected Pancreatic Cancer

The ASCO Post — Tue, 11 Aug 2026 01:42:58 +00:00

Researchers evaluated whether artificial intelligence applied to routine tumor histology can improve selection of adjuvant chemotherapy for patients with resected pancreatic cancer.

First-in-Class Bispecific ADC Shows Activity in Relapsed Extensive-Stage Small Cell Lung Cancer

The ASCO Post — Tue, 11 Aug 2026 01:59:16 +00:00

Investigators evaluated the efficacy and safety of izalontamab brengitecan in patients with relapsed extensive-stage small cell lung cancer.